The Global Market for Pain Management Drugs and Devices
The market for pain management drugs and devices was valued at $35.4 billion in 2012. Total market valued is expected to reach $41.5 billion in 2017 after increasing at a five-year compound annual growth rate of 3.2%.
- An overview of the global market for pain management drugs, which will address acute vs. chronic pain, treatments, and issues facing healthcare workers.
- Analyses of global market trends, with data from 2012, and projections of compound annual growth rates (CAGRs) through 2017.
- Examination of product categories, use of products, and the competitive landscape.
- Coverage of several significant market trends, including undertreatment issues, professional issues, managed care pain issues, trends in new therapies, product pipelines, generic participation, pain research, drug delivery, and patent expirations.
- Discussion of new regulatory requirements.
- Comprehensive company profiles of major players in the industry.
SCOPE AND FORMAT
This BCC Research report is designed to be a helpful business tool that will provide a thorough evaluation of the markets for pain management. The geographical scope of this study is global with a U.S. emphasis. This study will address acute versus chronic pain, treatments, and regulatory issues facing healthcare workers. Also provided is detailed information based on product categories, use of products, forecasts, and competitive analyses.
The report identifies two general segments of pain management:
Within the pharmaceuticals segment several sub-segments are discussed in detail including:
- Narcotic pain management.
- Non-narcotic pain management.
- Antimigraine treatments.
- Other drugs (including fibromyalgia treatments).
The device segment covers several product lines and specifically targets the largest product segments including:
- TENS and neuromuscular stimulators.
- Spinal cord stimulators.
- Other products (including electromagnetic therapies and other treatments).
Each market segment provides detailed information based on product categories, product use, forecasts, and competitive analyses.
MELISSA ELDER is a healthcare market analyst specializing in treatments, medical equipment and devices. As a research analyst for more than 20 years, she also worked in medical training and advanced medical technologies. She holds a B.S. degree in business management and is pursuing an MBA in health care management from California Coast University.
- The global market for pain management pharmaceuticals and devices amounted to $19.1 billion in 2008 and is expected to increase to $32.8 billion in 2013. The compound annual growth rate (CAGR) for the 5-year period is projected at 11.5%.
- The pharmaceuticals segment dominated the market at $17.6 billion in 2008. That figure is expected to increase to $30.2 billion in 2013, for a CAGR of 11.5%.
- The devices segment of the market generated $1.48 billion in sales in 2008 and is projected to increase to $2.5 billion in 2013, for a CAGR of 11.4%.
The global pain-management market is worth around $30.9 billion in 2007. It is forecasted to grow at a compound annual growth rate (CAGR) of 5.63% to reach $40.6 billion by the end of the forecast period, 2012.
The pharmaceuticals segment of the pain-management market is valued at $29 billion in 2007. It will be worth $38 billion by 2012 at a CAGR of 5.6%.
In 2007, market revenue from the medical devices segment is around $1.9 billion. This segment is predicted to grow at a CAGR of 6.5% to reach $2.6 billion by the end of 2012.
This report presents the forecast of the market for pain management through the year 2005. By 2005, it is anticipated that revenues will likely reach $32 billion, growing at an average annual rate of almost 12%.
Pain management pharmaceuticals currently hold the largest market revenue position, representing 97% and accounting for $16 billion of the total in 1999. Pharmaceuticals have long been the mainstay of pain management and it is anticipated that they will remain the largest market share throughout the forecast period.
Pain management devices account for 3%, representing $418.5 million in 1999. It is anticipated that the device segment will gain market revenue position due to technological advancements and a gradually declining cost increasing demand for current technologies